We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Precision Medicine for Rheumatoid Arthritis

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

In a new study, a Yale-led research team identified the mechanism of a gene that raises the risk of severe rheumatoid arthritis in susceptible individuals. The finding may lead to the development of treatment based on the genetic profiles of arthritis patients, the researchers said.

The study was published Nov. 21 in Proceedings of the National Academy of Sciences (PNAS).

Rheumatoid arthritis is a common autoimmune disease that affects an estimated 3 million people and is most prevalent in women. The disease, which destroys cartilage in joints, can lead to severe disability. In its most severe form, vascular inflammation and internal organ damage occur, leading to premature death.

To understand the disease mechanism, Yale professor of medicine Dr. Richard Bucala and his team focused on the disease-causing variants of the gene, MIF, which his lab had found to be associated with severe rheumatoid arthritis.

The research team conducted experiments with cells derived from the rheumatoid joint of patients who either had a disease-causing, high-expression variant of the MIF gene or a disease-protective, low-expression variant of the MIF gene. They found that high-expression MIF variants correlated with increased expression of the MIF receptor protein (CD44) and induced structural changes in the protein that occur in cancerous tissues. These cancerous properties in turn led to the destructive changes in the rheumatoid joint.

“We showed that the presence of the high-expression risk variant led to more MIF production and to structural alterations in a cell surface protein that had long been associated with invasive cancers,” said Bucala. “The high-expression MIF risk gene helps explain the cancer-like properties of the rheumatoid joint.”

This finding could lead to the application of MIF inhibitors, which the laboratory has developed for clinical testing in cancer and in autoimmunity, for severe rheumatoid arthritis in genetically susceptible patients. In the published study, the researchers used these drugs as well as new inhibitors to suppress the invasive effect of MIF on rheumatoid joint cells.

“It’s a precision-medicine approach to treating autoimmune disease,” Bucala noted. “Patients with a risk MIF genotype would be most effectively treated by such drugs.”

Source:

Story from Yale University. Original piece written by Ziba Kashef. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.

Reference:

Yoo, S.-A., Leng, L., Kim, B.-J., Du, X., Tilstam, P. V., Kim, K. H., … Bucala, R. (2016). MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1612717113